Volume 5.06 | Feb 17

Cancer Stem Cell News 5.06 February 17, 2016
Cancer Stem Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CSCN on Twitter
 
TOP STORY
Cell Marker Found for Leukemia-Initiating Capacity in Chronic Myelogenous Leukemia
Researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML — an inability to get patients off treatment. [Press release from University of Alabama at Birmingham discussing online publication in The Journal of Clinical Investigation] Press Release | Full Article
View Webinar: Genome Editing: From Modeling Disease to Novel Therapeutics
 
PUBLICATIONS (Ranked by impact factor of the journal)
Sca-1 Enriches for a Cancer Stem Cell-Like Subpopulation in Mouse Gastric Cancer
Researchers found that Sca-1 is a novel cancer stem cell enrichment marker that mediates TGF-β and Wnt/β-catenin signaling in mouse gastric cancer. [Stem Cells] Abstract

Nanoquinacrine Induced Apoptosis in Cervical Cancer Stem Cells through the Inhibition of Hedgehog-GLI1 Cascade: Role of GLI-1
To improve the pharmacokinetics and to study the anti-cervical cancer and anti-stem cells (CSCs) mechanism of Quinacrine (QC), a spherical nano particle of QC (NQC) was prepared and characterized. QC and NQC showed higher cytotoxicity in multiple cancer cells than the normal epithelial cells. [Sci Rep] Full Article

Regulatory Role of Hexosamine Biosynthetic Pathway on Hepatic Cancer Stem Cell Marker CD133 under Low Glucose Conditions
Cancer stem cells-like phenotypes and cell survival were investigated in cancer cells under low glucose conditions. As a result, hexosamine biosynthetic pathway inhibitor azaserine reduced CD133-positive subpopulation and CD133 expression under high glucose condition. [Sci Rep] Full Article

Oncometabolic Nuclear Reprogramming of Cancer Stemness
Using a systems biology approach, combining mathematical modeling, computation, and proof-of-concept studies with live cells, investigators found that an oncometabolite-driven pathological version of nuclear reprogramming increases the speed and efficiency of dedifferentiating committed epithelial cells into stem-like states with only a minimal core of stemness transcription factors. [Stem Cell Reports] Full Article | Graphical Abstract

mTOR Inhibition Decreases SOX2-SOX9 Mediated Glioma Stem Cell Activity and Temozolomide Resistance
The authors reveal SOX2-SOX9 as an oncogenic axis that regulates stem cell properties and chemoresistance. They identify that rapamycin abrogate SOX protein expression and provide evidence that a combination of rapamycin and temozolomide inhibits tumor growth in cells with high SOX2/SOX9. [Expert Opin Ther Targets] Abstract

Detection of ALDH1 Activity in Rabbit Hepatic VX2 Tumors and Isolation of ALDH1 Positive Cancer Stem Cells
In order to clarify the validity of the rabbit VX2 liver cancer model, investigators questioned if it expresses aldehyde dehydrogenase 1 (ALDH1) as a potential marker of cancer stem cells. [J Transl Med] Full Article

Requirement of CXCL12-CXCR7 Signaling for CD20 CD138 Double-Negative Population in Lymphoplasmacytic Lymphoma
Researchers investigated the plasticity of cancer-initiating cells of lymphoplasmacytic lymphoma, and found that hypoxia induced the conversion of CD20+ CD138 to CD20 CD138 phenotype. [Lab Invest] Abstract

Treatment of Colon Cancer with Oncolytic Herpes Simplex Virus in Preclinical Models
Scientists cultured colon cancer cells in stem cell medium to obtain colonosphere cells. These cells possessed the characteristics of cancer stem cells, with a high capacity of tumorigenicity, migration and invasion in vitro and in vivo. [Gene Ther] Abstract

Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells
 
REVIEWS
Cancer Stem Cells: Radioresistance, Prediction of Radiotherapy Outcome and Specific Targets for Combined Treatments
An increasing body of evidence complies with a higher radioresistance of cancer stem cells (CSCs) compared to the mass of tumor cells, supporting the use of CSC related biomarkers for prediction of radiotherapy outcome. Treatment individualization strategies for patient groups with vastly different risk of recurrence will most likely require application of more than one biomarker. [Adv Drug Deliv Rev] Full Article

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
 
INDUSTRY NEWS
Fluxion Biosciences Launches New Range of Circulating Tumor Cell (CTC) Recovery Kits- First Launch of Commercial Kits Targeting EMT Cells
Fluxion Biosciences, Inc. announced that it has launched two new kits for enhanced CTC isolation and recovery that are designed to work exclusively with the IsoFlux Liquid Biopsy system. [Fluxion Biosciences, Inc.] Press Release

VolitionRx Demonstrates 75 Percent Accuracy in Detecting Highest-Risk Pre-Cancerous Colorectal Adenomas with NuQ® Blood Test
VolitionRx Limited announced results demonstrating that the company’s NuQ® blood test accurately detected 75 percent of colorectal adenomas, or pre-cancerous polyps, that were most likely to become cancerous. [VolitionRx Limited] Press Release

Apogenix Receives €3 Million Grant for the Development of a Companion Diagnostic Test for Lead Immuno-Oncology Candidate APG101
Apogenix announced that it has received funding approval in the amount of €3 million from the German Federal Ministry of Education and Research for the so-called CancerMark project. [Apogenix] Press Release

From our sponsor: Studying ESCs or iPSCs? Request your free copy of the small molecules wallchart.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 12th International Conference of the Asian Clinical Oncology Society (ACOS)
April 8-10, 2016
New Delhi, India

Visit our events page to see a complete list of events in the cancer stem cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellowship – Cancer Stem Cell Biology (Fred Hutchinson Cancer Research Center)

NEW PhD Studentship – Various Positions in Cancer (Virginia Commonwealth University)

Faculty Position – Cancer Research (Various Areas) (The Jackson Laboratory)

Postdoctoral Fellowship – Cancer Epigenomics (Princess Margaret Cancer Centre )

Faculty Position – Radioimmunotherapy (Fred Hutchinson Cancer Research Center)

Director Manufacturing – Cell and Gene Therapy (Fred Hutchinson Cancer Research Center)

Lab Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center)

Post-Doc Fellowships – Integrative Analysis in Prostate and Breast Cancer (Baylor College of Medicine)

Research Scientist – Hematopoietic Stem Cell Transplantation (University of Chicago)

Staff Scientist – Cell Therapy Process Development (Fred Hutchinson Cancer Research Center)

Post-Doc Fellowship – Bioinformatics RNA Biology and Cancer (German Cancer Research Center)

Post-Doc Fellowship – Genetics and Genomics of Stem Cells (Albert Einstein College of Medicine of Yeshiva University)

Professor – Cancer Immunotherapy (Stanford Cancer Institute)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cancer Stem Cell News: Archives | Events | Contact Us